These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 6817447

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Variables that might affect the outcome of immune tolerance therapy in haemophiliacs with factor VIII inhibitors.
    Ehrenforth S, Kreuz W, Funk M, Auerswald G, Scharrer I.
    Thromb Haemost; 1994 Nov; 72(5):784-5. PubMed ID: 7900088
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
    Lozier JN, Santagostino E, Kasper CK, Teitel JM, Hay CR.
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
    [Abstract] [Full Text] [Related]

  • 46. Immune tolerance by intermittent factor VIII boluses in two high responder hemophilia A patients.
    Landolfi R, de Cristofaro R, Lazzareschi I, Riccardi R, Mariani G.
    Haematologica; 2000 Oct; 85(10 Suppl):73-4. PubMed ID: 11187877
    [Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Prevention and treatment of induced antibodies to clotting factors in hemophilia--applications of advances in immunology.
    Steinberg AD.
    Prog Clin Biol Res; 1984 Oct; 150():155-66. PubMed ID: 6431424
    [No Abstract] [Full Text] [Related]

  • 49. Treatment of the bleeding inhibitor patient.
    Astermark J.
    Semin Thromb Hemost; 2003 Feb; 29(1):77-86. PubMed ID: 12640569
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors.
    Ewing NP, Sanders NL, Dietrich SL, Kasper CK.
    JAMA; 1988 Jan 01; 259(1):65-8. PubMed ID: 3119878
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P, Plamenová I, Hollý P, Stasko J.
    Med Sci Monit; 2009 Jun 01; 15(6):CS105-11. PubMed ID: 19488019
    [Abstract] [Full Text] [Related]

  • 56. Acquired hemophilia and its treatment.
    Sultan Y.
    Blood Coagul Fibrinolysis; 1997 Aug 01; 8 Suppl 1():S15-8. PubMed ID: 9351531
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Factor VIII inhibitor treatment with high doses of F VIII.
    Stenbjerg S, Ingerslev J, Zachariae E.
    Thromb Res; 1984 Jun 15; 34(6):533-9. PubMed ID: 6429891
    [Abstract] [Full Text] [Related]

  • 59. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M, Sawamoto Y, Kamisue M, Shibata Y, Tuzi S, Kuwabara M, Tanaka I, Tanizawa T, Tanaka A, Ueda M, Kakishita E, Yoshioka A.
    Rinsho Ketsueki; 1996 Nov 15; 37(11):1303-8. PubMed ID: 8960666
    [Abstract] [Full Text] [Related]

  • 60. Use of an animal model to evaluate hemophilia therapies.
    Giles AR.
    Prog Clin Biol Res; 1984 Nov 15; 150():265-76. PubMed ID: 6431432
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.